Topic: Clinical Trial Results
Right now, Roche’s Tecentriq is the only I-O drug approved in triple negative breast cancer. And it looks like it’ll stay that way for awhile.
Pfizer's abrocitinib, a JAK1-specific inhibitor, has met all co-primary and key secondary endpoints in a late-stage eczema study.
New analysis found Mayzent had meaningful benefits on cognitive processing speed in patients with secondary progressive multiple sclerosis.
Eli Lilly had high hopes in oncology with its oncology drug, Lartruvo. Now, with the failed drug in full retreat, Lilly hopes to keep current patients.
Clovis Oncology's PARP inhibitor Rubraca didn't spur enough response to warrant continuing a phase 2 bladder cancer study.
Tuesday, April 9, 2019
Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.
Lilly's Lartruvo has been a key launch for its oncology business, but thanks to a phase 3 fail, it plans to stop promoting the drug.
Last May, Neurocrine’s Ingrezza failed a Tourette syndrome trial, prompting the company to design a new one. But the drug has failed that trial, too.
BMS' Opdivo just took another hit to its lung cancer aspirations. The I-O blockbuster flunked a small cell lung cancer trial soon after Roche posted a first-line win.
GSK touted data for what could be a promising vaccine against tuberculosis, a leading cause of death worldwide.